Heron Therapeutics: Looking For Entry Following HTX-011 PDUFA Extension [Seeking Alpha]
Heron Therapeutics, Inc. (HRTX)
Last heron therapeutics, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
herontherapeutics.gcs-web.com/investor-home
Company Research
Source: Seeking Alpha
Summary Heron Therapeutics reported encouraging preliminary Q4/2019 results revealing CINVANTI continues to record impressive growth. The FDA extended Heron’s HTX-011 PDUFA date to June. If approved, the Heron could have a unique non-opioid analgesic that could thwart the necessity of postop prescription opioids. I discuss my views on potential approval and how I plan on entering a pilot position following the PDUFA extension. Heron Therapeutics ( HRTX 3-month extension I intend to review the company’s recent commercial growth and preliminary 2019 results. In addition, I provide my views on HTX-011’s CRL and the likelihood of approval. Finally, I discuss my case for a buy and how I plan on starting a position ahead of HTX-011’s PDUFA. Preliminary 2019 Numbers Point to Growth Recently, the company reported preliminary Q4 numbers with CINVANTI and SUSTOL raking in about $34.8M in net product sales, which is up 21% year-over-year. For the full-year, CINVANTI and SUSTOL recorded roughly $
Show less
Read more
Impact Snapshot
Event Time:
HRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HRTX alerts
High impacting Heron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HRTX
News
- Heron Therapeutics, Inc. (NASDAQ: HRTX) is now covered by analysts at Capital One Financial Co.. They set an "overweight" rating and a $6.00 price target on the stock.MarketBeat
- Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain [Seeking Alpha]Seeking Alpha
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City [Yahoo! Finance]Yahoo! Finance
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York CityPR Newswire
- Heron Therapeutics, Inc. (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.MarketBeat
HRTX
Earnings
- 3/12/24 - Beat
HRTX
Sec Filings
- 4/19/24 - Form 4
- 4/19/24 - Form PRE
- 4/19/24 - Form 4
- HRTX's page on the SEC website